phenyl 6-chloromethyl-2-oxo-2H-1-benzopyran-3-carboxylate | 176770-30-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: phenyl 6-chloromethyl-2-oxo-2H-1-benzopyran-3-carboxylate
• 英文别名: phenyl 6-(chloromethyl)-2-oxo-2H-chromene-3-carboxylate；phenyl 6-(chloromethyl)-2-oxochromene-3-carboxylate
• CAS: 176770-30-2
• 化学式: C₁₇H₁₁ClO₄
• 分子量: 314.725
• InChiKey: VLAVQNSKKDLVGI-UHFFFAOYSA-N

物化性质

• 沸点：
  531.6±50.0 °C(Predicted)
• 密度：
  1.393±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  乌洛托品 、 phenyl 6-chloromethyl-2-oxo-2H-1-benzopyran-3-carboxylate 以 氯仿 为溶剂， 反应 18.0h， 以92%的产率得到phenyl 6-hexamethylenetetrammoniomethyl-2-oxo-2H-1-benzopyran-3-carboxylate; chloride
  参考文献：
  名称：

  6-Substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid derivatives in a new approach of the treatment of cancer cell invasion and metastasis

  摘要：

  Novel 6-substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid derivatives were synthesized and their potency in reducing the invasive behaviour of HT 1080 fibrosarcoma cells was evaluated. Structure-activity relationships were deduced from biological results and will be used in further design of new active compounds. In particular, the acetoxymethyl substituent found at the 6-position of previously described active compounds can be replaced by an acetamidomethyl substituent without loss of potency; while the presence of an aryl ester function at the 3-position was preferred to a thioester or an amide function to induce marked biological activity. This work confirms the interest of aryl esters of 6-substituted coumarin-3-carboxylic acids as potential new anti-cancer agents. (C) 2008 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2008.01.024
• 作为产物：
  描述：

  2-羟基-5-(羟基甲基)苯甲醛 在 哌啶 、 吡啶 、 盐酸 、 氯化亚砜 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 25.0h， 生成 phenyl 6-chloromethyl-2-oxo-2H-1-benzopyran-3-carboxylate
  参考文献：
  名称：

  3,6-Disubstituted Coumarins as Mechanism-Based Inhibitors of Thrombin and Factor Xa

  摘要：

  In this work, coumarins were screened on thrombin (THR) and factor Xa (FXa), two of the most promising targets for the development of anticoagulant drugs. This allowed us to highlight compound 30, characterized by a 2,5-dichlorophenyl ester in the 3-position and a chloromethyl moiety in the 6-position, as a very potent THR inhibitor (k(i)/K-I, = 37 000 M-1 s(-1)). Moreover, this compound exhibits good selectivity over FXa (168-fold) and trypsin (54-fold). The mechanism of inactivation was investigated in this series and significantly differs from that previously observed with (x-chymotrypsin. Indeed, the addition of hydrazine on the THR-inhibitor complex promotes a partial induced THR reactivation. This reactivation, confirmed by LC/MS, showed the resurgence of the native THR and a new dihydrazide complex. Docking experiments were then efficiently used to explain the trends observed in the enzymatic assays as well as to corroborate the postulated inhibition mechanism. Finally, the cell permeability of our derivatives was estimated using a computational approach.

  DOI：

  10.1021/jm050448g

文献信息

• [EN] USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES<br/>[FR] UTILISATION DE DÉRIVÉS DE COUMARINE POUR LA PRÉPARATION DE MÉDICAMENTS POUR LE TRAITEMENT DE MALADIES DE LA PEAU
  申请人：UNIV PARIS CURIE

  公开号：WO2013010963A1

  公开（公告）日：2013-01-24

  The invention relates to a compound of formula (I-1) wherein n equals 0 or 1, Z represents O or S, R1 represents one group chosen among the group consisting ofhydrogen, C1-C7 alkyl, substituted, or not, by a halogen, a hydroxyl or a O-R12 group, wherein R12 is a C1-C7 alkyl, a group CH2OCOR5 wherein R5 is chosen among a hydrogen atom and a C1-C7 alkyl, substituted or not by at least one halogen, a group O-R13, wherein R13 is chosen among hydrogen and a C1-C7 alkyl, an amine or a CH2-amine, R1 represents a group chosen among hydrogen and O-R14, wherein R14 is chosen among hydrogen and a C1-C7 alkyl, and R2 is chosen among the group consisting of a C1-C7 alkyl, a C3-C6 cycloalkyl, an aryl group, and an heteroaryl group for its use for the treatment of pathologies involving an excess of activity of at least one member of the kallikrein family.

  该发明涉及一种化合物，其化学式为（I-1），其中n等于0或1，Z代表O或S，R1代表在羟基、C1-C7烷基、经取代或未取代的氢、卤素、羟基或O-R12基团中选择的一种基团，其中R12是C1-C7烷基、CH2OCOR5基团中的一种，其中R5选择在氢原子和C1-C7烷基之间，经取代或未取代，至少含有一个卤素，O-R13基团中选择在氢和C1-C7烷基之间，胺或CH2-胺，R1代表在氢和O-R14之间选择的一种基团，其中R14选择在氢和C1-C7烷基之间，R2选择在C1-C7烷基、C3-C6环烷基、芳基和杂环芳基之间的一种基团，用于治疗涉及卡利克雷因家族至少一成员活性过量的病理。
• Use of coumarin derivatives for the preparation of drugs for treating skin diseases
  申请人：Université Pierre et Marie Curie - Paris 6

  公开号：EP2545916A1

  公开（公告）日：2013-01-16

  The invention relates to a compound of formula (I) wherein n equals 0 or 1, and wherein, if n=1, Z represents O or S, R1 represents at least one group chosen among the group consisting of hydrogen, a linear or branched, saturated or not, C1-C7 alkyl, substituted, or not, by a halogen, a group -CH2-O-CO-R5 wherein R5 is chosen among a hydrogen atom, and a linear or branched, saturated or not, C1-C7 alkyl, substituted or not by at least one halogen, and an amine, and R2 is chosen among the group consisting of a linear or branched, saturated or not C1-C7 alkyl, a C3-C6 cycloalkyl, an aryl group, and an heteroaryl group for its use for the treatment of pathologies involving an excess of activity of at least one member of the kallikrein family.

  该发明涉及一种具有公式（I）的化合物，其中n等于0或1，如果n=1，则Z代表O或S，R1代表至少选择自氢、一种线性或支链、饱和或非饱和的C1-C7烷基中的一种，该烷基可以被卤素取代或不取代，一个基团-CH2-O-CO-R5，其中R5选择自氢原子，以及一种线性或支链、饱和或非饱和的C1-C7烷基，该烷基可以被至少一个卤素取代或不取代，以及一种胺，R2选择自线性或支链、饱和或非饱和的C1-C7烷基中的一种，C3-C6环烷基，芳基和杂环芳基，用于治疗涉及至少一种卡利克雷因家族成员活性过高的病理的用途。
• Esters and Amides of 6-(Chloromethyl)-2-oxo-2<i>H</i>-1-benzopyran-3-carboxylic Acid as Inhibitors of α-Chymotrypsin:  Significance of the “Aromatic” Nature of the Novel Ester-Type Coumarin for Strong Inhibitory Activity
  作者：Lionel Pochet、Caroline Doucet、Marc Schynts、Nicole Thierry、Nicole Boggetto、Bernard Pirotte、Kai Y. Jiang、Bernard Masereel、Pascal de Tullio、Jacques Delarge、Michèle Reboud-Ravaux

  DOI：10.1021/jm960090b

  日期：1996.1.1

  activity toward bovine alpha-chymotrypsin and human leukocyte elastase. Both series behaved as time-dependent inhibitors of alpha-chymotrypsin, but ester-type coumarins were clearly more efficient than the corresponding amides in inactivating the serine proteinase. The best inactivations were observed with "aromatic" esters, in particular with meta-substituted phenyl esters such as m-chlorophenyl 6-(chlor

  合成了一系列6-（氯甲基）-2-氧代-2H-1-苯并吡喃-3-羧酸的酯和酰胺，并在体外评估了它们对牛α-胰凝乳蛋白酶和人白细胞弹性蛋白酶的抑制活性。这两个系列均表现为α-胰凝乳蛋白酶的时间依赖性抑制剂，但酯型香豆素在灭活丝氨酸蛋白酶方面显然比相应的酰胺更有效。用“芳族”酯，尤其是间位取代的苯基酯，例如间氯苯基6-（氯甲基）-2-氧代-2H-1-苯并吡喃-3-羧酸酯，观察到最好的灭活。最强大的α-胰凝乳蛋白酶灭活剂（在pH 7.5和25摄氏度下，激酶/ KI = 760,000 M-1 S-1）的报道。通常，香豆素衍生物不能显着抑制人白细胞弹性蛋白酶。
• USE OF COUMARIN DERIVATIVES FOR THE PREPARATION OF DRUGS FOR TREATING SKIN DISEASES
  申请人：UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)

  公开号：US20140148480A1

  公开（公告）日：2014-05-29

  A compound of formula (I-1) wherein n equals 0 or 1, Z represents O or S, R1 represents one group chosen among the group consisting of hydrogen, C1-C7 alkyl, substituted, or not, by a halogen, a hydroxyl or a —O—R12 group, wherein R12 is a C1-C7 alkyl, a group —CH 2 —O—CO—R5 wherein R5 is chosen among a hydrogen atom and a C1-C7 alkyl, substituted or not by at least one halogen, a group —O—R13, wherein R13 is chosen among hydrogen and a C1-C7 alkyl, an amine or a —CH 2 — amine, R′1 represents a group chosen among hydrogen and —O—R14, wherein R14 is chosen among hydrogen and a C1-C7 alkyl, and R2 is chosen among the group consisting of a C1-C7 alkyl, a C3-C6 cycloalkyl, an aryl group, and an heteroaryl group for the treatment of pathologies involving excess activity of at least one member of the kallikrein family.

  化合物的公式（I-1），其中n等于0或1，Z代表O或S，R1代表从以下组中选择的一组基团，该组基团由氢，C1-C7烷基组成，被卤素，羟基或—O—R12基团取代或未取代，其中R12是C1-C7烷基，一个基团—CH2—O—CO—R5，其中R5选择氢原子和C1-C7烷基，被至少一个卤素取代或未取代，一个基团—O—R13，其中R13选择氢和C1-C7烷基，胺或—CH2—胺，R'1代表选择氢和—O—R14之一的基团，其中R14选择氢和C1-C7烷基，而R2选择在由C1-C7烷基，C3-C6环烷基，芳基和杂芳基组成的一组中，用于治疗涉及至少一种卡利克雷因家族成员过度活性的病理情况。
• US9006466B2
  申请人：——

  公开号：US9006466B2

  公开（公告）日：2015-04-14